• Terumo CEO Hikaru Samejima discussed the aortic stent-graft recall at the November 12, 2026, second-quarter update.
• The recall is expected to cut FY26 revenue by JPY 8 billion and operating profit by JPY 41 billion.
• Global shipments of affected products have been suspended since late October 2026 following detection of endotoxin levels exceeding specifications.
• The Arsenal Medical acquisition closed October 2, 2026, for approximately USD 215 million, with additional milestone-based consideration, adding liquid embolic NeoCast.
• TBCT targets FY27 revenue growth of at least 5% and an adjusted operating profit increase of at least JPY 5 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terumo Corporation published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.